NVO241213C126000
- 0.01
- -0.02-66.67%
Novo-Nordisk A/S Newsroom
Novo Nordisk Says Catalent Buyout to Close Soon as Regulatory Conditions Met
Key Deals for the Week: Patterson, Hershey & Mondelez, AIG & Nippon and More
CFRA Initiates Novo-Nordisk A/S(NVO.US) With Hold Rating, Announces Target Price $122
Unusual Options Activity: YMM, SHAK and Others Attract Market Bets, YMM V/OI Ratio Reaches 100.0
Latest research confirms: Novo-Nordisk A/S Ozempic is associated with a rare risk of vision loss.
① A latest study confirms that Ozempic, a star drug from the Danish pharmaceutical giant Novo-Nordisk A/S, is associated with an increased risk of a rare eye disease that leads to vision loss; ② According to an analysis by Nordic researchers of years of patient records from Denmark and Norway, diabetic patients using Ozempic are more than twice as likely to develop NAION compared to patients using another diabetes medication.
Market Whales and Their Recent Bets on NVO Options
Novo Nordisk Shares Are Trading Lower Following a Report Suggesting a Study Linked Ozempic to an Increased Risk of a Rare Form of Vision Loss.
Express News | Novo Nordisk Shares Are Trading Lower Following a Report Suggesting a Study Linked Ozempic to an Increased Risk of a Rare Form of Vision Loss
'Ozempic Link to Rare Vision Loss Risk Confirmed in Study; Risk of Eye Condition Remains Low; Patients Should Be Aware; NAION Occurs When Loss of Blood Flow Damages Optic Nerve' - Bloomberg News
Express News | "Weight-Loss Drug Craze Appears To Be Curbing U.S. Obesity Epidemic; Obesity Is Down In The U.S. For The First Time In A Decade. A New Study Suggests Weight-Loss Drugs May Explain Why" - Bloomberg News
Ozempic Works on Kidney Disease, Regulator Says. Why Novo Nordisk Stock Is Falling.
NVO Gets Positive CHMP Opinion in EU for Ozempic Expanded Use in CKD
Eli Lilly and Co (LLY.US) Mounjaro has replaced Novo-Nordisk A/S (NVO.US) Wegovy as the new favorite weight loss drug in the United Kingdom.
The number of private individuals in the United Kingdom purchasing weight loss drugs is continuously increasing, with Eli Lilly and Co's Mounjaro gradually surpassing Novo-Nordisk A/S's Wegovy, becoming a new favorite among consumers.
Here's Why Novo Nordisk A/S (NVO) Fell in Q3
Telehealth Firm Ro Partners With Eli Lilly to Boost Access to Obesity Drug Zepbound
Novo Nordisk's Ozempic Gets EU Regulator Endorsement to Reduce Kidney Risks
Express News | European Medicines Agency's Committee For Medicinal Products For Human Use Adopted Positive Opinion For Update Of Novo Nordisk's Ozempic
TD Cowen Maintains Novo-Nordisk A/S(NVO.US) With Buy Rating, Maintains Target Price $155
Xi'an Global Printing (002799.SZ): Has maintained a good cooperative relationship with Eli Lilly and Co and Novo-Nordisk A/S.
Gelonghui reported on December 12 that Xi'an Global Printing (002799.SZ) stated on the investor interaction platform that the company has maintained a good cooperative relationship with Eli Lilly and Co, Novo-Nordisk A/S, and other enterprises. In the future, the company will continue to strengthen market development efforts and expand its customer base.
Catalent Gains After Report Sale to Novo Holdings Could Close Soon